Rango de valoración compuesto · conservador $68–$74 / razonable $110–$148 / optimista $202–$220. A $131.78, Dentro del rango de valor intrínseco razonable.
Al publicar $170.77 (2 de julio de 2026)
Barron's reported UnitedHealth will cover Guardant's Shield colorectal cancer blood test for about 40 million members.
Possible impact:May affect Shield adoption, reimbursement expectations and 2026 revenue visibility.
IBD reported the American Cancer Society added Shield as a colorectal cancer screening option for people aged 50 and older.
Possible impact:May affect physician adoption, commercial reimbursement odds and expectations for the screening business.
IBD reported FDA approval for the newer Guardant360 Liquid CDx, with a much broader genomic footprint than its predecessor.
Possible impact:May affect therapy-selection volumes, pricing expectations and views on 2027 revenue growth.
Automatically summarized from public sources; for context only, not investment advice.
Datos de EODHD, mostrados en la moneda de reporte; solo a título informativo, no constituye asesoramiento de inversión.
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
PróximamenteEsta sección se está completando; vuelve pronto.
PróximamenteEsta sección se está completando; vuelve pronto.
Aún no hay análisis sobre este valor en tu idioma.
